Fosamax Max Dose: How to Titrate Alendronate and What Comes After

What Is Alendronate and Why Is There a Max Dose?

Alendronate is an oral bisphosphonate that slows bone resorption by inhibiting osteoclast activity. The maximum approved dose for treating osteoporosis in women is 70 mg once weekly, which delivers the same weekly drug exposure as 10 mg daily. The FDA approved this ceiling based on the dose-ranging work done before and during the Fracture Intervention Trial. Going above that dose does not appear to produce additional benefit in bone mineral density (BMD), and it raises the risk of upper gastrointestinal adverse effects.

The concept of "titration" applies to alendronate differently than it does to, say, a hormone or a GLP-1 agonist. You are not gradually stepping up to find a personal therapeutic window. Instead, you are selecting one of two approved dose tiers based on your diagnosis: prevention (osteopenia with elevated fracture risk) versus treatment (osteoporosis by BMD criteria or prior fragility fracture). The dose is fixed within that tier.

Prevention vs. Treatment Tier

For prevention in postmenopausal women: 35 mg once weekly or 5 mg daily.

For treatment of osteoporosis in postmenopausal women: 70 mg once weekly or 10 mg daily.

Your clinician chooses the tier; there is no gradual escalation between them. If your T-score crosses the diagnostic threshold for osteoporosis, or if you sustain a fragility fracture while on the prevention dose, the clinical step is to move from the prevention tier to the treatment tier. That single step up from 35 mg to 70 mg weekly is the closest thing to "titration" that alendronate has.

Why the 70 mg Ceiling Exists

Dose-ranging studies conducted before FIT showed that doses above 10 mg daily did not produce meaningfully greater suppression of bone turnover markers, but did produce more esophageal irritation and gastrointestinal complaints. The FDA label reflects this: efficacy plateaus, but tolerability continues to decline. Prescribing above 70 mg weekly is off-label with no supportive evidence and real GI risk.

The FIT Trial: What the Evidence Actually Shows

The Fracture Intervention Trial (FIT) remains the foundational evidence base for alendronate in women. Published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55 to 81 with low femoral neck BMD and at least one vertebral fracture at baseline. Women randomized to alendronate 5 mg daily (later increased to 10 mg daily) showed a 47% reduction in new vertebral fractures compared to placebo over approximately 3 years.

Hip fracture risk fell by 51% in the alendronate arm among women who had a prior vertebral fracture at baseline. For women without a prior vertebral fracture (the FIT 2 arm), the hip fracture reduction was not statistically significant in the full group, though the subgroup with T-score below negative 2.5 did show benefit.

What FIT Tells You About Dose

FIT used a starting dose of 5 mg daily, which was stepped up to 10 mg daily partway through the trial as dose-finding work clarified the optimal exposure. This mid-trial step-up is sometimes misread as a "titration" protocol. It was not. It was a protocol amendment based on emerging pharmacokinetic data, not a patient-level response to inadequate efficacy. For you as an individual patient, this means there is no equivalent "give it a few months and see, then step up" protocol built into the evidence.

FLEX Extension: How Long Is Long Enough?

The FLEX (Fracture Intervention Trial Long-Term Extension) study, published in JAMA 2006, followed FIT participants who were reassigned to continue alendronate or switch to placebo for an additional 5 years. Women who continued alendronate for a total of 10 years maintained higher BMD and lower bone turnover markers compared to those who stopped after 5 years. However, the reduction in clinical fractures in the continuation group was modest and restricted largely to clinical vertebral fractures. Non-vertebral and hip fracture rates did not differ significantly between 5-year and 10-year treatment groups. This supports the concept of a drug holiday for many women after 5 years, rather than indefinite dose escalation.

Who Gets Which Dose and When: A Life-Stage View

Bone health is not a postmenopausal-only story. Alendronate is prescribed across several distinct life stages in women, and the indication, dose tier, and duration differ meaningfully across them.

Postmenopausal Women

This is the population with the deepest evidence base. Estrogen withdrawal at menopause accelerates bone resorption, and BMD can fall 1-3% per year in the early postmenopausal years. Alendronate is FDA-approved for this group at both prevention and treatment doses. Most guidelines, including The Menopause Society's 2023 position statement, recommend initiating pharmacotherapy when a postmenopausal woman has a T-score at or below negative 2.5, or a T-score between negative 1.0 and negative 2.5 with a 10-year FRAX hip fracture probability at or above 3% or major osteoporotic fracture probability at or above 20%.

The treatment dose for this group is 70 mg weekly. Full stop.

Perimenopausal Women

Perimenopause begins the estrogen decline that accelerates bone loss. A perimenopausal woman with a DXA scan showing osteopenia and a high FRAX score may be prescribed the prevention dose (35 mg weekly). Moving to the treatment dose happens if the T-score deteriorates to negative 2.5 or worse, or if she fractures. There is no evidence that starting at the treatment dose in a perimenopausal woman with osteopenia produces superior outcomes compared to starting at the prevention dose.

Premenopausal Women

Alendronate use in premenopausal women is largely off-label except for glucocorticoid-induced osteoporosis. The American College of Rheumatology recommends bisphosphonates in premenopausal women on long-term glucocorticoids (prednisone equivalent 7.5 mg or more daily for 3 or more months) with moderate or high fracture risk. In this setting, alendronate 70 mg weekly or 10 mg daily is typically used, with careful attention to contraception requirements (see the pregnancy section below).

Women With PCOS

Women with polycystic ovary syndrome have complex bone health profiles. Hyperandrogenism may partially protect trabecular bone, but chronic anovulation and low estrogen states in lean PCOS phenotypes can reduce BMD. A 2021 meta-analysis in Fertility and Sterility found mixed BMD outcomes across PCOS subtypes. Alendronate is not a first-line bone health intervention for PCOS; correcting the underlying hormonal environment comes first. When alendronate is prescribed for a woman with PCOS who also has osteoporosis, dosing follows the same tiers as for any premenopausal or perimenopausal woman.

Pregnancy and Lactation Safety

Alendronate is contraindicated in pregnancy. This is not a relative contraindication. Bisphosphonates incorporate into bone matrix and have a skeletal half-life measured in years to decades. Animal studies show fetal skeletal harm at doses producing maternal systemic exposures comparable to human therapeutic exposures. Human data on alendronate in pregnancy is limited to case reports and small series, and several cases of fetal hypocalcemia and neonatal bone abnormalities have been described with bisphosphonate exposure in pregnancy.

The FDA label for alendronate classifies it as Pregnancy Category C, which means animal studies show adverse fetal effects and there are no adequate well-controlled human studies. In practical terms: if there is any chance you could become pregnant, this requires active discussion with your clinician before starting.

Contraception Requirement

Any premenopausal woman prescribed alendronate should use reliable contraception throughout treatment and for a period after stopping. Because bisphosphonates persist in bone for years, even stopping alendronate does not immediately eliminate fetal risk. The ACOG Practice Bulletin on osteoporosis advises that the safest approach for a premenopausal woman who plans future pregnancy is to delay bisphosphonate therapy if possible, using other agents or lifestyle measures in the interim.

Lactation

Alendronate transfer into breast milk has not been formally studied in humans. Given the minimal oral bioavailability of alendronate (less than 1%), the theoretical infant exposure through breast milk is likely very low. However, because no human lactation data exists and the drug's bone incorporation means it is not rapidly cleared, most clinicians recommend avoiding alendronate while breastfeeding and choosing alternative bone protection strategies for the postpartum period if needed.

How Quickly Can You Increase the Dose?

The honest answer: there is no approved titration schedule above 70 mg weekly because there is no approved dose above 70 mg weekly.

Within the two approved tiers, moving from the prevention dose (35 mg weekly) to the treatment dose (70 mg weekly) can happen at any point when clinical criteria are met. There is no required waiting period between tiers. If a DXA scan reveals a T-score that crosses into osteoporosis territory, or if you sustain a fragility fracture, the step-up can happen at the next prescription. No gradual dose creep is needed; the pharmacokinetics of alendronate do not require a ramp-up period.

Bone turnover markers, such as serum CTX (C-telopeptide of type I collagen) or urinary NTX, can confirm that alendronate is being absorbed and is biologically active. A 2005 study in the Journal of Bone and Mineral Research showed that CTX suppression is detectable within 3 months of starting alendronate and reaches a plateau by 6 months. If your CTX is not suppressed after 6 months on 70 mg weekly, the question to ask is whether you are absorbing the drug correctly, not whether the dose should go higher.

Absorption Failures: The Most Common "Dose Problem"

Alendronate has notoriously poor oral bioavailability (less than 1% under fasting conditions; even lower with food, coffee, or other medications). Most apparent "dose failures" are absorption failures. Before any discussion of dose escalation or switching agents, your clinician should review:

• Are you taking alendronate on an empty stomach, first thing in the morning?
• Are you waiting at least 30 minutes before eating, drinking anything except plain water, or taking other medications?
• Are you remaining upright (sitting or standing) for at least 30 minutes after the dose?
• Do you have conditions that reduce GI absorption, such as celiac disease, bariatric surgery, or inflammatory bowel disease?

Correcting any of these factors often resolves what looked like inadequate response without any change in the prescribed dose.

When the Max Dose Is Not Enough: What Comes Next

If you have been adherent on 70 mg weekly alendronate for 12 months or more, your administration technique is correct, and your DXA scan still shows declining BMD or you sustain a new fracture, the clinical framework for next steps has three branches, not an escalation branch:

Branch 1: Switch within bisphosphonate class. Zoledronic acid (Reclast) given as a 5 mg intravenous infusion once yearly bypasses GI absorption entirely. For women with absorption issues, celiac disease, or severe GI intolerance, IV zoledronate is often the solution to what looked like alendronate failure. The HORIZON Key Fracture Trial showed a 70% reduction in vertebral fractures and a 41% reduction in hip fractures with annual IV zoledronate in postmenopausal women with osteoporosis.

Branch 2: Switch to a different mechanism entirely. Denosumab (Prolia) is a RANK-L inhibitor given as a 60 mg subcutaneous injection every 6 months. It consistently outperforms bisphosphonates on BMD gains at the spine and hip in head-to-head studies. The FREEDOM trial demonstrated a 68% reduction in vertebral fracture risk and a 40% reduction in hip fracture risk over 3 years in postmenopausal women.

Branch 3: Add an anabolic agent. Teriparatide (Forteo) and abaloparatide (Tymlos) are parathyroid hormone analogs that build new bone rather than simply slowing its loss. Romosozumab (Evenity) is a sclerostin inhibitor with both anabolic and anti-resorptive properties. These are reserved for women with severe osteoporosis, multiple fractures, or proven failure on anti-resorptive therapy. After completing an anabolic course, a bisphosphonate is typically restarted to preserve the gains.

Jumping to a higher alendronate dose is not a branch in this framework because the pharmacology does not support it.

Drug Holiday: Does More Time on the Max Dose Help?

A drug holiday means intentionally pausing alendronate after a period of treatment, relying on the drug's long skeletal retention to maintain some anti-fracture effect. This is a realistic consideration for many women, not an edge case.

The American Society for Bone and Mineral Research (ASBMR) 2022 Task Force report recommends:

• Lower fracture risk (T-score above negative 2.5 at hip after 3-5 years of treatment, no prior hip or vertebral fracture): consider a drug holiday of 2-3 years.
• Higher fracture risk (T-score at or below negative 2.5 at hip, or prior fracture): consider continuing for 10 years before a holiday, or switching to a non-bisphosphonate agent.

Staying on the max dose indefinitely does not prevent atypical femoral fracture (AFF). The risk of AFF with alendronate is rare but real: approximately 3.2 to 50 per 100,000 person-years depending on duration, with risk rising markedly after 5 years of use. A drug holiday after 5 years in appropriate candidates reduces AFF risk without substantially increasing vertebral fracture risk in lower-risk women.

Who This Is Right For, and Who It Is Not

Alendronate 70 mg Weekly Is Appropriate For

• Postmenopausal women with osteoporosis (T-score at or below negative 2.5)
• Postmenopausal women with prior fragility fracture regardless of T-score
• Perimenopausal women with osteoporosis and high FRAX score
• Premenopausal women on long-term glucocorticoids with moderate to high fracture risk (off-label; requires reliable contraception)
• Women with breast cancer treatment-related bone loss on aromatase inhibitors (alendronate 70 mg weekly has shown BMD preservation in this group per SABRE trial data)

Alendronate Is Not Appropriate For

• Pregnant women or women planning pregnancy in the near term
• Women with esophageal abnormalities (stricture, achalasia) or inability to sit/stand for 30 minutes
• Women with eGFR below 35 mL/min (kidney clearance is insufficient)
• Women with hypocalcemia (correct before starting)
• Women who have already completed 5-10 years at the treatment dose and qualify for a drug holiday
• Women with severe osteoporosis and multiple fractures who need an anabolic agent first

Monitoring: What to Track and When

Alendronate is not a "prescribe and forget" drug. Active monitoring determines whether the current dose tier is working or whether a clinical decision point has arrived.

Bone Mineral Density

Repeat DXA at 1-2 years after starting. For women on the treatment dose who are stable, every 2 years is standard. If BMD declines by more than the least significant change (typically 3-5% at the spine, 4-6% at the hip on most DXA machines), that is a signal to reassess adherence, absorption, and whether a class switch is needed.

Bone Turnover Markers

Serum CTX is the most commonly used marker. A CTX drawn after 3-6 months on therapy should show suppression below the premenopausal reference range (roughly below 300 pg/mL on most assays), indicating adequate drug effect. If CTX is not suppressed, absorption or adherence is the first suspect.

Calcium and Vitamin D

Alendronate does not work in a calcium or vitamin D-deficient state. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) recommends 1,000-1,200 mg of calcium daily (diet plus supplement) and 800-1,000 IU of vitamin D3 daily for postmenopausal women. Deficiencies should be corrected before starting alendronate.

Practical Dosing Instructions Every Woman Should Hear

Correct administration is as important as the dose number on the label.

• Take alendronate first thing in the morning, before any food, drink, or other medication.
• Swallow the tablet whole with at least 6 to 8 ounces of plain water. No coffee, juice, mineral water, or milk.
• Remain upright (sitting, standing, or walking) for at least 30 minutes after the dose.
• Do not take it lying down; esophageal exposure to the tablet increases mucosal injury risk dramatically.
• On the weekly formulation (70 mg), choose the same day of the week every week and mark it.
• If you miss a dose, take it the next morning. Do not double up on the same day.